Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022:2434:333-341.
doi: 10.1007/978-1-0716-2010-6_23.

Delivery of Antisense Oligonucleotides to the Mouse Brain by Intracerebroventricular Injections

Tom Metz  1 , Elsa C Kuijper  2 , Willeke M C van Roon-Mom  2
Affiliations

Delivery of Antisense Oligonucleotides to the Mouse Brain by Intracerebroventricular Injections

Tom Metz et al. Methods Mol Biol. 2022.

Abstract

The use of antisense oligonucleotides (AONs) is a promising therapeutic strategy for central nervous system disorders. However, the delivery of AONs to the central nervous system is challenging because their size does not allow them to diffuse over the blood-brain barrier (BBB) when injected systemically. The BBB can be bypassed by administering directly into the brain. Here we describe a method to perform single and repeated intracerebroventricular injections into the lateral ventricle of the mouse brain.

Keywords: Antisense oligonucleotides; Cannula; Intracerebroventricular injections; Stereotactic surgery.

PubMed Disclaimer

References

    1. Aartsma-Rus A (2017) FDA approval of Nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides. Nucl Acid Ther 27(2):67–69. https://doi.org/10.1089/nat.2017.0665 doi: 10.1089/nat.2017.0665. - DOI - PubMed
    1. Cummings CJ, Zoghbi HY (2000) Fourteen and counting: unraveling trinucleotide repeat diseases. Hum Mol Genet 9(6):909–916. https://doi.org/10.1093/hmg/9.6.909 doi: 10.1093/hmg/9.6.909. - DOI - PubMed
    1. Nakamura K, Jeong SY, Uchihara T, Anno M, Nagashima K, Nagashima T, Ikeda S, Tsuji S, Kanazawa I (2001) SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet 10(14):1441–1448. https://doi.org/10.1093/hmg/10.14.1441 doi: 10.1093/hmg/10.14.1441. - DOI - PubMed
    1. Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, Baumann T, Gerlach I, Schobel SA, Paz E, Smith AV, Bennett CF, Lane RM (2019) Targeting huntingtin expression in patients with Huntington’s disease. N Engl J Med 380(24):2307–2316. https://doi.org/10.1056/NEJMoa1900907 doi: 10.1056/NEJMoa1900907. - DOI - PubMed
    1. Evers MM, Tran HD, Zalachoras I, Meijer OC, den Dunnen JT, van Ommen GJ, Aartsma-Rus A, van Roon-Mom WM (2014) Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification. Nucl Acid Ther 24(1):4–12. https://doi.org/10.1089/nat.2013.0452 doi: 10.1089/nat.2013.0452. - DOI - PubMed

Publication types

Substances

LinkOut - more resources